Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

VTAK vs AVR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AVR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 3–4 Matrix Metrics)

AVR Overall Winner 6-Pillar Tally: VTAK 2 – 3 AVR (1 Tie) Matrix Metrics: VTAK 4 – 3 AVR

As of Nov 16, 2026, Anteris Technologies Global Corp. (AVR) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas AVR carries 48.2/100 (HOLD) at $5.70 (N/M Forward P/E, -4880.4% operating margin).

  • Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. AVR 48.2/100 HOLD), AVR captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-4880.4% vs. -388.1% operating margin) and revenue trajectory (+21.0% vs. +380.7% YoY).
  • Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile AVR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About VTAK vs AVR
VTAK NYSE American
Catheter Precision, Inc.
Surgical & Medical Instruments & Apparatus
$0.15
-0.66% 1D
Market Cap $548,639
TTM Revenue $1.9M
Forward P/E N/M
Beta / 30D Vol 0.19β · 76% Vol
Unified Composite Score
58.1 / 100 HOLD
Tech 72.0 Fund 70.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -53.4%), weak momentum, RSI 33
RSI-14: 33.2 · SMA20: $0.16 · SMA50: $0.21
AVR NASDAQ Head-to-Head Winner
Anteris Technologies Global Corp. Common Stock
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$5.70
+5.17% 1D
Market Cap $528.4M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 1.56β · 77% Vol
Unified Composite Score
48.2 / 100 HOLD
Tech 58.0 Fund 49.0 Flow 57.0 Mom 68.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -15.2%), weak momentum, RSI 42
RSI-14: 42.5 · SMA20: $5.93 · SMA50: $6.90

6-Pillar Scorecard Institutional Category Breakdown (VTAK 2 – 3 AVR)

Columns: Metric · VTAK · AVR
1. Valuation Multiples VTAK
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 0.3x 133.9x
2. Growth & Scale VTAK
Revenue Growth (YoY) +380.7% +21.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.9M $2.3M
Market Cap $548,639 $528.4M
3. Profitability & Quality AVR
Gross Margin 47.7% 75.8%
Operating Margin -388.1% -4880.4%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -111.3% -93.3%
4. Balance Sheet & Cash Flow AVR
Cash Generation (TTM) -$10M EBITDA -$94M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.87 Book/Sh · -111.3% ROE $216M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AVR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 58.5% (52nd %ile)
Put/Call OI Skew N/A 0.66x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: VTAK (4) vs AVR (3)
Institutional Metric VTAK AVR Criterion Row Edge
Market Capitalization
Scale
$548,639 $528.4M Larger Scale AVR
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+380.7% +21.0% Higher Growth VTAK
Operating Margin (TTM)
Profitability
-388.1% -4880.4% Higher Margin VTAK
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-111.3% -93.3% Higher ROE AVR
52-Week Range Position
Momentum
1% ($0–$3) 31% ($3–$11) Stronger Trend AVR
Beta / 30D Volatility
Risk Regime
0.19β · 76% Vol 1.56β · 77% Vol Lower Realized Risk VTAK
Unified Institutional Score
Composite Signal
58.1 / 100 (HOLD) 48.2 / 100 (HOLD) Higher Composite VTAK
Trailing 12M Revenue (USD)
Operating Scale
$1.9M $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
47.7% 75.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.3x EV/Rev N/M PEG · 133.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) -$94M ($216M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AVR +14.52 pp
VTAK: -24.76% · AVR: -10.24%
3M Horizon AVR +53.23 pp
VTAK: -80.29% · AVR: -27.06%
6M Horizon AVR +123.94 pp
VTAK: -83.76% · AVR: +40.18%
1Y Horizon AVR +196.06 pp
VTAK: -92.63% · AVR: +103.43%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period VTAK Revenue AVR Revenue VTAK Op. Margin AVR Op. Margin Margin Leader
FY2018 $10M N/A -498.0% N/A VTAK
FY2019 $10M N/A -801.9% N/A VTAK
FY2020 $0M N/A -13668.3% N/A VTAK
FY2021 $0M N/A -133027.3% N/A VTAK
FY2022 $0M N/A -192578.6% N/A VTAK
FY2023 $0M N/A -17674.0% N/A VTAK
FY2024 $0M $0M -2676.9% -2899.4% VTAK
FY2025 $0M $0M -2581.6% -4908.2% VTAK

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
VTAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AVR BREAKDOWN
101d in phase · OBV NEUTRAL
Current IV 58.5%
IV Percentile 52nd %ile
Put/Call OI Skew 0.66x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AVR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
VTAK Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $548,639 market capitalization and -388.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
AVR Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $528.4M market capitalization and -4880.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ VTAK vs AVR Key Questions & Quantitative Answers

As of Nov 16, 2026, Anteris Technologies Global Corp. (AVR) is the stronger overall head-to-head candidate over Catheter Precision, Inc. (VTAK) in the Tradestie Institutional Equity Comparison Engine, winning 3–4 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas AVR carries 48.2/100 (HOLD) at $5.70 (N/M Forward P/E, -4880.4% operating margin). Composite vs. Pillar Nuance: While VTAK currently prints a higher short-term Unified Composite Score (58.1/100 HOLD vs. AVR 48.2/100 HOLD), AVR captures the overall institutional head-to-head verdict (3–4 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-4880.4% vs. -388.1% operating margin) and revenue trajectory (+21.0% vs. +380.7% YoY). Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile AVR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 42.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VTAK leads the Growth & Scale pillar: VTAK posts +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin), compared with AVR at +21.0% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (75.8% gross margin, -4880.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VTAK cumulative revenue shifted +0.0% while AVR shifted N/A. In operating R&D and SG&A reinvestment, VTAK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AVR.

VTAK screens cheaper on headline valuation multiples. VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin), whereas AVR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 133.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTAK (-111.3% ROE) versus AVR (-93.3% ROE) capital efficiency.

In options market volatility and institutional positioning, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk). By comparison, AVR carries 58.5% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.66x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.